	Serum Institute of India Pvt. Ltd.	DIPHTHERIA AND TETANUS VACCINE ADSORBED FOR ADULTS AND ADOLESCENTS	Summary of Product Characteristics
---	--	---	---------------------------------------

1. NAME OF THE MEDICINAL PRODUCT

Diphtheria and Tetanus Vaccine Adsorbed For Adults and Adolescents

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each single 0.5 ml human dose contains

Diphtheria Toxoid ≤ 5 Lf (≥ 2 IU)

Tetanus Toxoid ≥ 5 Lf (≥ 40 IU)

Adsorbed on Aluminium Phosphate, Al⁺⁺⁺ ≤ 1.25 mg

Preservative: 0.005 % Thiomersal


3. PHARMACEUTICAL FORM

Suspension for injection

4. CLINICAL PARTICULARS

4.1 Therapeutic Indication

For primary vaccination and revaccination of adults and adolescents, who are having contraindications of DTP. Primary vaccination and revaccination of children older than 7 years. In order to prevent allergic reactions to the protein of Diphtheria toxoid, the quantity of the toxoid has been markedly reduced. After a primary immunisation course of either DTP or Td for adults may be used as a booster at intervals of approximately 10 years, but with a minimum of at least one year between doses. It can safely replace monovalent tetanus toxoid (TT) vaccine including during pregnancy. The vaccine can be safely and effectively given simultaneously with BCG, Measles, Polio Vaccine (IPV and OPV), Hepatitis B and Yellow Fever Vaccine, Haemophilus Influenzae type b and Varicella vaccine vitamin A supplementation.

	Serum Institute of India Pvt. Ltd.	DIPHTHERIA AND TETANUS VACCINE ADSORBED FOR ADULTS AND ADOLESCENTS	Summary of Product Characteristics
---	--	---	---------------------------------------

4.2 Posology and Method of Administration

Posology

Two injections of 0.5 ml at least four weeks apart followed by a third injection 6 to 12 months after the second dose. The vaccine should also be given as a booster immunization every 5 to 10 years.

Method of Inoculation

The vaccine should be injected intramuscularly. The preferred site for injection is deltoid muscles. Care should be taken not to inject into the blood vessel or the skin. Only sterile syringes and needles should be used for each injection. The vaccine should be well shaken before use.

Once opened, multi-dose vials should be kept between +2°C and +8°C. Multi-dose vials of Diphtheria and tetanus vaccine adsorbed for adults and adolescents vaccine from which one or more doses of vaccine have been removed during an immunisation session may be used in subsequent immunisation sessions for upto a maximum of 28 days, provided that all of the following conditions are met (as described in the WHO policy statement: Handling of multi dose vaccine vials after opening, WHO/IVB/14.07):

- The vaccine is currently prequalified by WHO;
- The vaccine is approved for use for up to 28 days after opening the vial, as determined by WHO;
- The expiry date of the vaccine has not passed;
- The vaccine vial has been, and will continue to be, stored at WHO - or manufacturer recommended temperatures; furthermore, the vaccine vial monitor, if one is attached, is visible on the vaccine label and is not past its discard point, and the vaccine has not been damaged by freezing.

The vaccine should be visually inspected for any foreign particulate matter and / or variation of physical aspect prior to administration. In event of either being observed, discard the vaccine.

	Serum Institute of India Pvt. Ltd.	DIPHTHERIA AND TETANUS VACCINE ADSORBED FOR ADULTS AND ADOLESCENTS	Summary of Product Characteristics
---	--	---	---------------------------------------

4.3 Contraindication

The vaccine should not be given to persons who showed a severe reaction to a previous dose of Diphtheria and Tetanus vaccine.

A history of systemic allergic or neurologic reactions following a previous dose of Td is an absolute contraindication for further use.

Immunization should be deferred during the course of an acute illness. Vaccination of persons with severe, febrile illness should generally be deferred until these persons have recovered. However, the presence of minor illnesses such as mild upper respiratory infections with or without fever should not preclude vaccination.

4.4 Special Warning and Precaution


ADRENALINE INJECTION (1:1000) MUST BE IMMEDIATELY AVAILABLE SHOULD AN ACUTE ANAPHYLACTIC REACTION OCCURS DUE TO ANY COMPONENT OF THE VACCINE.

For treatment of severe anaphylaxis the initial dose of adrenaline is 0.1 - 0.5 mg (0.1-0.5 ml of 1:1000 injection) given subcutaneously or intramuscularly. The single dose should not exceed 1 mg (1 ml). For infants and children the recommended dose of adrenaline is 0.01 mg/kg (0.01 ml/Kg of 1:1000 adrenaline injection). A single pediatric dose should not exceed 0.5 mg (0.5 ml). The mainstay in the treatment of severe anaphylaxis is the prompt use of adrenaline, which can be life-saving. It should be used at the first suspicion of anaphylaxis.

As with the use of all vaccines, the vaccinated should be monitored for no less than 30 minutes, due to the possibility of the occurrence of immediate and early allergic reactions. Hydrocortisone and antihistamines should also be available in addition to supportive measures such as oxygen inhalation.

Special care must be taken to ensure that the injection does not enter the blood vessels.

IT IS EXTREMELY IMPORTANT WHEN THE PARENT, GUARDIAN OR AN ADULT PATIENT RETURNS FOR THE NEXT DOSE IN THE SERIES, THE PARENT, GUARDIAN, OR ADULT PATIENT SHOULD BE QUESTIONED

	Serum Institute of India Pvt. Ltd.	DIPHTHERIA AND TETANUS VACCINE ADSORBED FOR ADULTS AND ADOLESCENTS	Summary of Product Characteristics
---	--	---	---------------------------------------

CONCERNING OCCURRENCE OF ANY SYMPTOMS AND/OR SIGNS OF AN ADVERSE REACTION AFTER THE PREVIOUS DOSE

IMMUNE DEFECIENCY

Individuals infected with human immunodeficiency virus (HIV), both asymptomatic and symptomatic, should be immunized with Diphtheria and Tetanus Vaccine Adsorbed For Adults and Adolescents according to standard schedules.

4.5 Interaction With other Medicinal Products, Other Interactions

If Td and TIG or Diphtheria Antitoxin are administered concurrently, separate syringes and separate sites should be used.

As with other Intramuscular injections, use with caution in patients on anticoagulant therapy.

Immunosuppressive therapies, including irradiation, antimetabolites, alkylating agents, cytotoxic drugs and corticosteroids used in greater than physiologic doses, may reduce the immune response to vaccines.

4.6 Pregnancy and Lactation


Diphtheria and Tetanus Vaccine Adsorbed For Adults and Adolescents is safe to be administered to pregnant women. Infact, it is recommended in pregnant women, for prophylaxis against neonatal tetanus.

4.7 Effects On Ability To Drive And Use Machines

Diphtheria and Tetanus Vaccine Adsorbed For Adults and Adolescents is not reported to have any influence on the ability to drive and use machines.

4.8 Adverse Reactions

Reactions are generally mild and confined to the site of injection. Some inflammation may occur together with transient fever, malaise and irritability. Occasionally a nodule may develop at the site of injection but this is rare.

	Serum Institute of India Pvt. Ltd.	DIPHTHERIA AND TETANUS VACCINE ADSORBED FOR ADULTS AND ADOLESCENTS	Summary of Product Characteristics
---	--	---	---------------------------------------

4.9 Overdose

No case of overdose has been reported.

5. PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic Properties

Pharmacotherapeutic Group: Vaccines

Tetanus toxoid, combinations with diphtheria toxoid, ATC Code: J07AM51

Mechanism of action

Diphtheria and Tetanus Vaccine Adsorbed For Adults and Adolescents stimulates the development of antibodies against the diphtheria and tetanus toxin.

	Serum Institute of India Pvt. Ltd.	DIPHTHERIA AND TETANUS VACCINE ADSORBED FOR ADULTS AND ADOLESCENTS	Summary of Product Characteristics
---	--	---	---------------------------------------

Immunological Data:

Clinical trials performed to assess immunogenicity and reactogenicity of the vaccine proved that the vaccine is immunogenic.

In a study in Hyderabad, in 706 children in the age group of 7 to 17 years, 98% and 94.7% children were protected following vaccination and 88% and 65.1% showed long term protection for tetanus and diphtheria, respectively.

In a phase IV study of Td vaccine in 62 adults aged more than 30 years, the seroprotection for diphtheria increased from 88% before vaccination to 100% following vaccination, while 100% subjects had seroprotection before as well as after vaccination

5.2 Pharmacokinetics Properties

Pharmacokinetic studies are not required for vaccines.

5.3 Preclinical Safety Data

No Data Available

6. PHARMACEUTICAL PROPERTIES

6.1 List of Excipients

Aluminium Phosphate (Prepared from Aluminium chloride, Sodium Chloride, Sodium Acetate Trihydrate and Trisodium phosphate Dodecahydrate)

Thiomersal


Water for Injection

6.2 Incompatibilities

In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.

6.3 Shelf Life

Thirty six months from date of manufacture.

	Serum Institute of India Pvt. Ltd.	DIPHTHERIA AND TETANUS VACCINE ADSORBED FOR ADULTS AND ADOLESCENTS	Summary of Product Characteristics
---	--	---	---------------------------------------

6.4 Special Precautions for storage

The vaccine should be stored in dry and dark place at a temperature between 2-8°C.

Transportation should also be at 2-8°C.

DO NOT FREEZE.

6.5 Nature and Contents of Packaging

1 Dose Ampoule Clear white tubular type I glass ampoule with One Point Cut (OPC) mechanism


1 Dose Ampoule with syringe and needle

10 and 20 Dose Vial: Clear white tubular type I vial; sealed with rubber stopper and flip-off Aluminium cap.

Note: All pack sizes may not be marketed.

6.6 Instructions regarding the preparation of medicinal products for its use and handling

Only sterile needles and syringes should be used for each injection. The vaccine should be well shaken before use.

	Serum Institute of India Pvt. Ltd.	DIPHTHERIA AND TETANUS VACCINE ADSORBED FOR ADULTS AND ADOLESCENTS	Summary of Product Characteristics
---	--	---	---------------------------------------

7. MARKETING AUTHORISATION HOLDER

Serum Institute of India Pvt. Ltd.

212/2, Hadapsar, Pune-411028, INDIA.

8. MARKETING AUTHORISATION NUMBER(S)

--

**9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE
AUTHORISATION**

--

10. DATE OF REVISION:

--